Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 04 June 2014 | By Alexander Gaffney, RAC,
The US Food and Drug Administration (FDA) has released an updated and final list of pathogens that are eligible for special incentives under the 2012 Generating Antibiotics Incentives Now (GAIN) provisions of the Food and Drug Administration Safety and Innovation Act (FDASIA).
The GAIN Act was passed in an attempt to incentivize the development of new antibiotics—a response to both growing rates of microbial resistance to antibiotics and a dearth of new antibiotic products in manufacturers' pipelines.
One of the GAIN Act's main provisions is Section 505E, which grants companies an additional five years of market exclusivity if they develop an antibiotic intended for a "qualified infectious disease." However, the act failed to describe which diseases are "qualified," leaving that distinction up to FDA regulators.
The statute laid out some, but not all, qualifications. For example, a "qualifying pathogen" had to be one with the "potential to pose a serious threat to public health." Legislators had identified gram-positive pathogens, multi-drug resistant gram-negative bacteria, multi-drug resistant tuberculosis (TB) and Clostridium difficile (c-diff) as being definite additions to the list, but left it up to FDA to generate a more exhaustive one.
For more on the GAIN Act and Qualified Infection Diseases, please see Focus' 11 June 2013 story, "FDA Looks to Spur Antibiotic Drug Development by Adding 18 Pathogens to Incentives List."
In June 2013, FDA releases a proposed rule listing 18 pathogens which, if targeted by a product, would qualify a product for GAIN Act incentives like additional market exclusivity.
Those qualifying pathogens were as follows:
However, FDA has now released a final rule amending that list, adding several pathogens that were not in its draft form.
The three new qualifying pathogens are:
All 18 of the draft pathogens remain on the list.
However, the impact of the list is not necessarily uniform. The language of the GAIN Act does not explicitly state that all products intended to treat qualifying pathogens are automatically eligible for Qualified Infectious Disease Product (QIDP), and neither does it prevent products intended to treat non-qualifying infectious diseases from obtaining QIDP status.
The QIDP status operates on a separate definition, and products eligible for the status are those which are “antibacterial or antifungal drug[s] for human use intended to treat serious or life-threatening infections."
FDA said its hands were tied by the statute, and that there was little it could do. As it explained:
"Qualifying pathogens are “pathogen[s]… that ha[ve] the potential to pose a serious threat to public health,” whereas QIDPs are certain human “drugs…intended to treat serious or life-threatening infections” (emphasis added). Most importantly, many pathogens with the potential to seriously threaten public health may cause varying levels of morbidity and mortality in a given individual depending on the site of infection, the person infected, the level of antimicrobial resistance present in the infecting pathogen, and other factors."
At least one commenter said the effect of this is to undermine congressional intent, and argued that the qualifying infectious pathogens list was intended to create certainty for manufacturers seeking to develop antibiotic therapies.
The final rule also determines that vaccine products are ineligible for consideration for QIDP designation under the GAIN Act due to their regulation under the Public Health Service Act (PHSA), and not the Federal Food, Drug and Cosmetic Act (FD&C Act).
Federal Register Notice: Food and Drug Administration Safety and Innovation Act: List of Qualifying Pathogens
Tags: GAIN Act, QIDP, Antibiotic, Antimicrobial, Qualified Infectious Disease Product, Qualified Infectious Disease
Regulatory Focus newsletters
All the biggest regulatory news and happenings.